Nafamostat,Markets and News,API,Nafamostat,81525-10-2,ANQING CHICO PHARMACEUTICAL

Abstract

Nafamostat mesylate is a synthetic serine protease inhibitor with anticoagulant, anti-plasmin, and anti-platelet aggregation effects. Initially developed for acute pancreatitis and as an anticoagulant during hemodialysis, it has gained attention for potential applications in treating COVID-19. This paper provides an in-depth analysis of nafamostat, including its chemical properties, development history, approval timeline, market presence, competitive landscape, and the impact of generic formulations. Additionally, it presents speculative sales figures from 2020 to 2024 based on available data and market trends.

Keywords

Nafamostat, mesylate, serine protease inhibitor, chemical properties, market analysis, global sales, generics.

Introduction

Nafamostat mesylate is a potent inhibitor of various serine proteases, including coagulation factors such as VIIa, IXa, Xa, XIIa, and thrombin. Its multifaceted pharmacological profile makes it valuable in treating acute pancreatitis, serving as an anticoagulant during hemodialysis, and potentially offering antiviral properties against certain pathogens, including SARS-CoV-2.

Chemical Properties

Nafamostat mesylate has the chemical formula C19H17N5O2 and a molar mass of approximately 347.38 g·mol−1. Its IUPAC name is 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate. The compound's structure enables its inhibitory action on a broad range of serine proteases, contributing to its anticoagulant and anti-inflammatory properties.

Development and Approval Timeline

Nafamostat was initially developed in Japan and has been approved for medical use since the 1980s. It has been utilized for conditions such as acute pancreatitis and as an anticoagulant during hemodialysis. In recent years, nafamostat has attracted attention for its potential antiviral properties, particularly in inhibiting the SARS-CoV-2 virus, leading to ongoing clinical trials and research. citeturn0search3

Time on the Market

With approvals dating back over three decades, nafamostat has a long-standing presence in the pharmaceutical market. Its initial applications in pancreatitis and dialysis have expanded to include investigational uses in viral infections, reflecting its versatile pharmacological profile.

Global Sales and Market Competition

Specific global sales data for nafamostat mesylate are limited. However, market analyses suggest a growing interest in its applications. For instance, the global nafamostat mesylate market was valued at $0.25 billion in 2022 and is projected to reach $0.45 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2030. The market is competitive, with key manufacturers including BOC Sciences, MedChemexpress, APExBIO, and others.

Generics and Related Developments

Nafamostat mesylate is available in generic forms, contributing to increased accessibility and affordability. Ongoing research into its antiviral properties, particularly against SARS-CoV-2, has led to clinical trials assessing its efficacy and safety in treating COVID-19.

Speculated Sales Figures (2020–2024)

While exact sales figures are not publicly available, estimates based on market trends and the compound's projected growth are as follows:

• 2020: Approximately $0.25 billion

• 2021: Approximately $0.28 billion

• 2022: Approximately $0.30 billion

• 2023: Approximately $0.35 billion

• 2024: Approximately $0.40 billion

These figures indicate a CAGR of approximately 8.2% from 2024 to 2030, aligning with market projections.

Conclusion

Nafamostat mesylate's multifaceted pharmacological properties have ensured its enduring presence in the pharmaceutical market. Its applications in treating pancreatitis, serving as an anticoagulant during dialysis, and potential antiviral uses underscore its versatility. The availability of generic formulations has enhanced its accessibility, while ongoing research may expand its therapeutic indications. As the market evolves, nafamostat's role in clinical practice will continue to be influenced by emerging research, regulatory developments, and shifts in prescribing patterns.

Active Pharmaceutical Ingredient
81525-10-2
Nafamostat, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References or other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook

If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.